Capdevila J, et al. - Whether active treatment in patients with asymptomatic, unresectable neuroendocrine tumors (NETs) would offer a survival benefit was investigated via this meta-analysis of pooled results from 6 clinical trials that compared active treatment vs placebo in patients with an asymptomatic, metastatic NET. Concerning active treatment (octreotide, lanreotide, sunitinib, everolimus, Lu-Dotatate) and tumors (gastrointestinal, pancreas, lung), the trials were heterogenous. In line with findings from recent clinical trials, better survival outcomes in relation to active treatment vs placebo were evident in this study. Across a broad spectrum of patient profiles and diverse medical treatments for metastatic NETs, these findings were obtained. Early treatment in most patients is supported as there are no reliable prognostic factors to know a priori which patients are unlikely to benefit from active treatment.